ESMO Lung Cancer 2022 – Gérard Zalcman

Gérard Zalcman discusses recent findings regarding the duration of immune checkpoint inhibitor treatment in patients with NSCLC, expectations of checkpoint inhibitor therapy in the setting of unresectable malignant pleural mesothelioma and how the treatment of patients with malignant pleural mesothelioma might be further optimized based on molecular findings.

Here is the full ESMO 2022 Solid Tumors report.